232 related articles for article (PubMed ID: 30554527)
21. A national approach to pharmacovigilance: The case of India as a growing hub of global clinical trials.
Dylan Fernandes S; Anoop NV; Castelino LJ; Narayana Charyulu R
Res Social Adm Pharm; 2019 Jan; 15(1):109-113. PubMed ID: 29602659
[TBL] [Abstract][Full Text] [Related]
22. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
Santoro A; Genov G; Spooner A; Raine J; Arlett P
Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
[TBL] [Abstract][Full Text] [Related]
23. Pharmacovigilance activities in ASEAN countries.
Suwankesawong W; Dhippayom T; Tan-Koi WC; Kongkaew C
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1061-9. PubMed ID: 27174034
[TBL] [Abstract][Full Text] [Related]
24. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
[TBL] [Abstract][Full Text] [Related]
25. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
[TBL] [Abstract][Full Text] [Related]
26. Surveillance of Drug Safety During Pregnancy: Insight in Current International Activities, Future Intentions and Need for Support of National Pharmacovigilance Centres.
Kant A; de Vries L; Rolfes L
Drug Saf; 2019 Jan; 42(1):35-43. PubMed ID: 30284215
[TBL] [Abstract][Full Text] [Related]
27. Pharmacovigilance in resource-limited countries.
Olsson S; Pal SN; Dodoo A
Expert Rev Clin Pharmacol; 2015; 8(4):449-60. PubMed ID: 26041035
[TBL] [Abstract][Full Text] [Related]
28. Opportunities and challenges of pharmacovigilance in special populations: a narrative review of the literature.
Li Y; Wu Y; Jiang T; Xing H; Xu J; Li C; Ni R; Zhang N; Xiang G; Li L; Li Z; Gan L; Liu Y
Ther Adv Drug Saf; 2023; 14():20420986231200746. PubMed ID: 37780667
[TBL] [Abstract][Full Text] [Related]
29. Impact of increased focus on pharmacovigilance on knowledge and attitude towards adverse drug reaction reporting among medical students in India.
Katyal J; Arora E; Gupta YK
Int J Risk Saf Med; 2020; 31(1):15-24. PubMed ID: 31594254
[TBL] [Abstract][Full Text] [Related]
30. Veterinary pharmacovigilance. Part 2. Veterinary pharmacovigilance in practice -- the operation of a spontaneous reporting scheme in a European Union country -- the UK, and schemes in other countries.
Woodward KN
J Vet Pharmacol Ther; 2005 Apr; 28(2):149-70. PubMed ID: 15842305
[TBL] [Abstract][Full Text] [Related]
31. Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
Bhushan S; Ray RS; Prakash J; Singh GN
Clin Ther; 2019 Nov; 41(11):2252-2262. PubMed ID: 31543285
[TBL] [Abstract][Full Text] [Related]
32. [Direct reporting by patients of adverse drug reactions in Spain].
Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
34. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.
Baldo P; Francescon S; Fornasier G
Int J Clin Pharm; 2018 Aug; 40(4):748-753. PubMed ID: 30094557
[TBL] [Abstract][Full Text] [Related]
35. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
36. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
37. Health Professionals' Knowledge, Attitudes and Practices about Pharmacovigilance in India: A Systematic Review and Meta-Analysis.
Bhagavathula AS; Elnour AA; Jamshed SQ; Shehab A
PLoS One; 2016; 11(3):e0152221. PubMed ID: 27010447
[TBL] [Abstract][Full Text] [Related]
38. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year.
Singh P; Agrawal M; Hishikar R; Joshi U; Maheshwari B; Halwai A
Indian J Pharmacol; 2017; 49(6):432-437. PubMed ID: 29674797
[TBL] [Abstract][Full Text] [Related]
39. Reporting of adverse drug reactions in India: A review of the current scenario, obstacles and possible solutions.
Mulchandani R; Kakkar AK
Int J Risk Saf Med; 2019; 30(1):33-44. PubMed ID: 30175985
[TBL] [Abstract][Full Text] [Related]
40. Adverse drug reactions: trends in a tertiary care hospital.
Rehan HS; Chopra D; Sah RK; Mishra R
Curr Drug Saf; 2012 Nov; 7(5):384-8. PubMed ID: 23150923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
